Chua Terence C, Yan Tristan D, Yap Zhu L, Horton Matthew D, Fermanis Gary G, Morris David L
Department of Surgery, University of New South Wales, St George Hospital, Kogarah, Sydney, NSW, Australia.
J Surg Oncol. 2009 Apr 1;99(5):292-5. doi: 10.1002/jso.21230.
Pleural dissemination of pseudomyxoma peritonei (PMP) is considered an advanced/terminal disease. We review our experience with thoracic cytoreductive surgery (CRS) and intraoperative hyperthermic intrathoracic chemotherapy (HITHOC) for the treatment of pleural recurrence of PMP following previous intraabdominal surgery.
An observational study of five patients with pleural dissemination from PMP treated with thoracic CRS and intraoperative HITHOC with mitomycin C for 90 min at 41.5 degrees C.
There were three men. The mean age was 46.5 (10.5) years. Postoperatively, one patient developed Grade I, one patient developed Grade III and one patient developed Grade IV postoperative complication. Two patients had an unremarkable postoperative recovery. Only one patient has died 38 months since treatment from abdominal complication of this disease with no evidence of thoracic disease. The four surviving patients are still alive 4.6-47.4 months after treatment. Two patients have evidence of an intraabdominal recurrence.
Thoracic CRS and intraoperative HITHOC is a safe and effective procedure to treat pleural dissemination from PMP. Long-term disease-free survival can be achieved from this treatment for which no other potentially curative therapy has been described.
腹膜假黏液瘤(PMP)的胸膜播散被认为是一种晚期/终末期疾病。我们回顾了我们采用胸壁细胞减灭术(CRS)及术中胸腔热灌注化疗(HITHOC)治疗既往腹部手术后PMP胸膜复发的经验。
一项对5例PMP胸膜播散患者的观察性研究,这些患者接受了胸壁CRS及术中使用丝裂霉素C在41.5摄氏度下进行90分钟的HITHOC治疗。
有3名男性。平均年龄为46.5(10.5)岁。术后,1例患者出现I级并发症,1例患者出现III级并发症,1例患者出现IV级并发症。2例患者术后恢复情况良好。自治疗后38个月,仅1例患者因该疾病的腹部并发症死亡,无胸腔疾病证据。4例存活患者在治疗后4.6至47.4个月仍存活。2例患者有腹腔复发证据。
胸壁CRS及术中HITHOC是治疗PMP胸膜播散的一种安全有效的方法。这种治疗可实现长期无病生存,而此前尚无其他可能治愈性的治疗方法被描述。